Charles Schwab Investment Management Inc. Sells 5,689 Shares of Jasper Therapeutics, Inc. $JSPR

Charles Schwab Investment Management Inc. reduced its stake in Jasper Therapeutics, Inc. (NASDAQ:JSPR) by 17.6% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 26,648 shares of the company’s stock after selling 5,689 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.18% of Jasper Therapeutics worth $115,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Corton Capital Inc. purchased a new position in Jasper Therapeutics during the first quarter worth about $113,000. Wells Fargo & Company MN grew its position in Jasper Therapeutics by 106.7% during the fourth quarter. Wells Fargo & Company MN now owns 7,415 shares of the company’s stock worth $159,000 after buying an additional 3,828 shares in the last quarter. Tema Etfs LLC purchased a new position in Jasper Therapeutics during the fourth quarter worth about $266,000. Barclays PLC grew its position in Jasper Therapeutics by 13.6% during the fourth quarter. Barclays PLC now owns 18,334 shares of the company’s stock worth $392,000 after buying an additional 2,188 shares in the last quarter. Finally, Wellington Management Group LLP raised its position in Jasper Therapeutics by 13.9% during the fourth quarter. Wellington Management Group LLP now owns 27,069 shares of the company’s stock valued at $579,000 after purchasing an additional 3,310 shares in the last quarter. Hedge funds and other institutional investors own 79.85% of the company’s stock.

Jasper Therapeutics Stock Performance

JSPR stock opened at $2.69 on Friday. Jasper Therapeutics, Inc. has a fifty-two week low of $2.27 and a fifty-two week high of $26.05. The business’s 50 day moving average price is $3.41 and its two-hundred day moving average price is $4.47. The company has a market capitalization of $43.71 million, a price-to-earnings ratio of -0.45 and a beta of 2.77.

Jasper Therapeutics (NASDAQ:JSPR) last posted its earnings results on Wednesday, August 13th. The company reported ($1.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.54). Sell-side analysts forecast that Jasper Therapeutics, Inc. will post -4.47 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on JSPR shares. Royal Bank Of Canada downgraded Jasper Therapeutics from an “outperform” rating to a “sector perform” rating and set a $5.00 price target on the stock. in a research report on Tuesday, July 8th. Cantor Fitzgerald downgraded Jasper Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Monday, July 7th. Oppenheimer lowered their price target on Jasper Therapeutics from $80.00 to $65.00 and set an “outperform” rating on the stock in a research report on Thursday, May 15th. BMO Capital Markets restated a “market perform” rating on shares of Jasper Therapeutics in a research report on Tuesday, July 8th. Finally, JMP Securities lowered their price target on Jasper Therapeutics from $70.00 to $12.00 and set a “market outperform” rating on the stock in a research report on Tuesday, July 8th. Six analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $28.75.

Jasper Therapeutics Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.